823 related articles for article (PubMed ID: 22094129)
21. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
[TBL] [Abstract][Full Text] [Related]
22. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
[TBL] [Abstract][Full Text] [Related]
23. [Liver transplantation for familial amyloid polyneuropathy].
Adams D; Slama M; Samuel D
Presse Med; 2010 Jan; 39(1):17-25. PubMed ID: 19419835
[TBL] [Abstract][Full Text] [Related]
24. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.
Conceição I; González-Duarte A; Obici L; Schmidt HH; Simoneau D; Ong ML; Amass L
J Peripher Nerv Syst; 2016 Mar; 21(1):5-9. PubMed ID: 26663427
[TBL] [Abstract][Full Text] [Related]
25. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
Berg I; Thor S; Hammarström P
Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
[TBL] [Abstract][Full Text] [Related]
27. Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.
Hund E
Appl Clin Genet; 2012; 5():37-41. PubMed ID: 23776379
[TBL] [Abstract][Full Text] [Related]
28. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity.
Ikeda S; Nakazato M; Ando Y; Sobue G
Neurology; 2002 Apr; 58(7):1001-7. PubMed ID: 11940682
[TBL] [Abstract][Full Text] [Related]
29. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy.
Koike H; Ando Y; Ueda M; Kawagashira Y; Iijima M; Fujitake J; Hayashi M; Yamamoto M; Mukai E; Nakamura T; Katsuno M; Hattori N; Sobue G
J Neurol Sci; 2009 Dec; 287(1-2):178-84. PubMed ID: 19709674
[TBL] [Abstract][Full Text] [Related]
30. Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review.
Martens B; De Pauw M; De Bleecker JL
Acta Neurol Belg; 2018 Jun; 118(2):179-185. PubMed ID: 29524093
[TBL] [Abstract][Full Text] [Related]
31. Clinical and pathological findings of non-Val30Met TTR type familial amyloid polyneuropathy in Japan.
Ikeda S; Takei Y; Tokuda T; Nakazato M; Ando Y
Amyloid; 2003 Aug; 10 Suppl 1():39-47. PubMed ID: 14640041
[TBL] [Abstract][Full Text] [Related]
32. Extremely Early Onset Transthyretin Familial Amyloid Polyneuropathy with a Leu55Pro Mutation: A Pediatric Case Report and Literature Review.
Lee YJ; Oh J; Hwang SK; Lee EJ; Yang DH; Kim YJ; Kwon S; Hyun MC
Neuropediatrics; 2019 Oct; 50(5):322-326. PubMed ID: 31319424
[TBL] [Abstract][Full Text] [Related]
33. Hereditary transthyretin-related amyloidosis.
Finsterer J; Iglseder S; Wanschitz J; Topakian R; Löscher WN; Grisold W
Acta Neurol Scand; 2019 Feb; 139(2):92-105. PubMed ID: 30295933
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus.
Kato-Motozaki Y; Ono K; Shima K; Morinaga A; Machiya T; Nozaki I; Shibata-Hamaguchi A; Furukawa Y; Yanase D; Ishida C; Sakajiri K; Yamada M
J Neurol Sci; 2008 Jul; 270(1-2):133-40. PubMed ID: 18410945
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Pain in Familial Amyloid Polyneuropathy.
Ng Wing Tin S; Planté-Bordeneuve V; Salhi H; Goujon C; Damy T; Lefaucheur JP
J Pain; 2015 Nov; 16(11):1106-14. PubMed ID: 26291275
[TBL] [Abstract][Full Text] [Related]
36. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy.
Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y
J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783
[TBL] [Abstract][Full Text] [Related]
37. Severe amyloid deposition in mammary glands of familial amyloid polyneuropathy patients.
Tokuda T; Takei Y; Takayama B; Hoshii Y; Ikeda S
Amyloid; 2007 Sep; 14(3):249-53. PubMed ID: 17701472
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report].
Miyazaki Y
Nihon Ronen Igakkai Zasshi; 2017; 54(1):75-80. PubMed ID: 28202889
[TBL] [Abstract][Full Text] [Related]
39. An amyotrophic lateral sclerosis-like syndrome revealing an amyloid polyneuropathy associated with a novel transthyretin mutation.
Lozeron P; Lacroix C; Theaudin M; Richer A; Gugenheim M; Adams D; Misrahi M
Amyloid; 2013 Sep; 20(3):188-92. PubMed ID: 23914756
[TBL] [Abstract][Full Text] [Related]
40. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]